Last 22 quarters of trend data · Healthcare · Drug Manufacturers - General
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
EV/EBITDA has compressed 82.7% YoY to 1.4x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 10.13 | — | 4.38 | 4.32 | 11.28 | 8.88 | 3.47 | 6.90 | 6.03 | 1.69 | 18.87 | 5.48 | 8.52 |
| — | — | +26.3% | -37.4% | +87.2% | +424.7% | -81.6% | +26.0% | -29.3% | -89.8% | +187.1% | -40.3% | +32.7% | |
| P/S Ratio | 0.30 | 0.31 | 0.43 | 0.39 | 0.64 | 0.61 | 0.79 | 0.83 | 0.75 | 0.58 | 0.73 | 0.83 | 0.98 |
| — | -49.2% | -44.7% | -52.6% | -14.2% | +5.2% | +7.2% | +0.6% | -23.6% | -51.8% | -24.6% | -39.0% | -31.1% | |
| P/B Ratio | 2.10 | 2.06 | 3.07 | 3.44 | 7.17 | 8.21 | 10.08 | 37.17 | 101.19 | — | — | — | — |
| — | -74.9% | -69.5% | -90.8% | -92.9% | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | 4.67 | 3.48 | — | 3.76 | 19.11 | 4.46 | — | 2.93 | 5.40 | — | 25.10 |
| — | — | -75.6% | -22.0% | — | +28.4% | +253.9% | — | — | -66.8% | -63.1% | — | -32.4% | |
| EV / EBITDA | 1.16 | 1.43 | 6.12 | 6.52 | 7.23 | 8.22 | 7.06 | 7.36 | 6.78 | 8.02 | 10.83 | 7.68 | 7.91 |
| — | -82.7% | -13.3% | -11.5% | +6.6% | +2.5% | -34.8% | -4.2% | -14.3% | -29.4% | +45.5% | -6.2% | +8.3% | |
| EV / EBIT | 1.47 | 1.98 | 7.37 | 7.51 | 13.66 | 11.55 | 9.73 | 9.09 | 8.85 | 12.81 | 14.83 | 8.89 | 9.73 |
| — | -82.8% | -24.2% | -17.4% | +54.3% | -9.9% | -34.4% | +2.2% | -9.0% | -4.4% | +63.2% | -19.2% | +21.1% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Organon & Co.'s operating margin was 15.6% in Q4 2025, down 6.8 pp QoQ and down 3.0 pp YoY. The trailing four-quarter average of 20.0% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 10.5% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 54.1% | 50.4% | 53.5% | 54.8% | 55.6% | 56.3% | 58.3% | 58.4% | 59.0% | 57.3% | 59.7% | 60.2% | 62.3% |
| — | -10.5% | -8.3% | -6.2% | -5.8% | -1.7% | -2.3% | -2.9% | -5.3% | -5.5% | -6.9% | -4.3% | -3.0% | |
| Operating Margin | 20.7% | 15.6% | 22.3% | 20.5% | 21.5% | 18.6% | 24.7% | 24.0% | 25.5% | 19.5% | 15.3% | 24.2% | 25.6% |
| — | -16.1% | -9.4% | -14.9% | -15.8% | -4.8% | +61.4% | -0.7% | -0.4% | -0.0% | -44.0% | -18.1% | -25.5% | |
| Net Margin | 3.0% | -13.6% | 10.0% | 9.1% | 5.8% | 6.8% | 22.7% | 12.1% | 12.4% | 34.2% | 3.8% | 15.0% | 11.5% |
| — | -298.7% | -56.0% | -25.0% | -53.6% | -80.0% | +494.3% | -19.4% | +7.7% | +369.8% | -74.1% | +1.9% | -48.2% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 27.1% | -22.6% | 19.5% | 22.7% | 17.2% | 22.6% | 112.7% | 203.1% | 418.8% | — | — | — | — |
| — | -200.2% | -82.7% | -88.8% | -95.9% | — | — | — | — | — | — | — | — | |
| ROA | — | — | 1.2% | 1.1% | 0.7% | 0.8% | 2.9% | 1.6% | 1.7% | 4.7% | 0.5% | 2.2% | 1.6% |
| — | — | -59.0% | -32.9% | -60.5% | -82.2% | +446.5% | -27.1% | +3.0% | +368.8% | -75.5% | +0.9% | -50.2% | |
| ROIC | 19.8% | 3.5% | 3.0% | 2.7% | 2.7% | 2.6% | 3.5% | 3.6% | 3.8% | 3.0% | 2.2% | 3.8% | 3.9% |
| — | +37.9% | -15.9% | -23.5% | -27.8% | -13.3% | +57.2% | -6.4% | -3.4% | -0.4% | -48.8% | -22.3% | -30.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 9.74 | 12.14 | 16.52 | 19.14 | 17.75 | 60.11 | 181.54 | — | — | — | — |
| — | — | -45.1% | -79.8% | -90.9% | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | 19.75 | 21.44 | 21.07 | 24.29 | 19.06 | 19.15 | 18.19 | 24.01 | 29.54 | 19.53 | 19.31 |
| — | — | +3.6% | +11.9% | +15.8% | +1.2% | -35.5% | -1.9% | -5.8% | -9.9% | +61.6% | +13.8% | +25.7% | |
| Current Ratio | — | — | 1.75 | 1.65 | 1.67 | 1.60 | 1.70 | 1.64 | 1.65 | 1.54 | 1.63 | 1.66 | 1.61 |
| — | — | +2.9% | +0.9% | +1.4% | +3.5% | +4.8% | -1.3% | +2.3% | -1.3% | +5.4% | +5.3% | -0.1% | |
| Quick Ratio | — | — | 1.20 | 1.13 | 1.15 | 1.11 | 1.21 | 1.17 | 1.15 | 1.09 | 1.15 | 1.16 | 1.13 |
| — | — | -0.8% | -3.2% | -0.2% | +1.8% | +5.2% | +1.2% | +1.7% | -6.1% | -1.3% | -1.9% | -5.7% | |
| Interest Coverage | 2.55 | 1.94 | 2.80 | 2.47 | 2.62 | 2.24 | 3.10 | 2.95 | 3.16 | 2.42 | 1.73 | 2.95 | 2.98 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 22 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonOrganon & Co.'s current P/E is 10.1x. The average P/E over the last 3 quarters is 6.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Organon & Co.'s current operating margin is 20.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Organon & Co.'s business trajectory between earnings reports.